[
    [
        {
            "time": "2021-10-26",
            "original_text": "王宗合三季报：加仓山西汾酒、药明康德、福斯特、三峡能源",
            "features": {
                "keywords": [
                    "三季报",
                    "加仓",
                    "山西汾酒",
                    "药明康德",
                    "福斯特",
                    "三峡能源"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒",
                    "医药",
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "王宗合三季报：加仓山西汾酒、药明康德、福斯特、三峡能源",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "凯莱英公布三季报 前三季净利增加37.26%",
            "features": {
                "keywords": [
                    "凯莱英",
                    "三季报",
                    "净利",
                    "37.26%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英公布三季报 前三季净利增加37.26%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "高瓴大幅减仓“眼茅”爱尔眼科，葛兰却在加仓，究竟谁是时间的朋友？",
            "features": {
                "keywords": [
                    "高瓴",
                    "减仓",
                    "爱尔眼科",
                    "葛兰",
                    "加仓"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "高瓴大幅减仓“眼茅”爱尔眼科，葛兰却在加仓，究竟谁是时间的朋友？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "图解凯莱英三季报：第三季度单季净利润同比增39.30%",
            "features": {
                "keywords": [
                    "凯莱英",
                    "三季报",
                    "净利润",
                    "39.30%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "图解凯莱英三季报：第三季度单季净利润同比增39.30%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "新鲜出炉！凯莱英：2021年第三季度净利润约2.66亿元，同比增长39.3%",
            "features": {
                "keywords": [
                    "凯莱英",
                    "三季报",
                    "净利润",
                    "2.66亿",
                    "39.3%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新鲜出炉！凯莱英：2021年第三季度净利润约2.66亿元，同比增长39.3%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "凯莱英：前三季度净利润同比增长37.26%",
            "features": {
                "keywords": [
                    "凯莱英",
                    "三季报",
                    "净利润",
                    "37.26%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英：前三季度净利润同比增长37.26%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "1.36亿！CDMO公司发起大型并购",
            "features": {
                "keywords": [
                    "CDMO",
                    "并购",
                    "1.36亿"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "1.36亿！CDMO公司发起大型并购",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "华西证券给予凯莱英买入评级：全球小分子CDMO行业领先者，资本开支加速和战略重视长尾客户驱动公司业绩加速",
            "features": {
                "keywords": [
                    "华西证券",
                    "凯莱英",
                    "买入评级",
                    "CDMO",
                    "资本开支",
                    "长尾客户"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华西证券给予凯莱英买入评级：全球小分子CDMO行业领先者，资本开支加速和战略重视长尾客户驱动公司业绩加速",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "华西证券：给予凯莱英买入评级",
            "features": {
                "keywords": [
                    "华西证券",
                    "凯莱英",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CDMO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华西证券：给予凯莱英买入评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "Wind医药：每日行业动态（2021-10-26）",
            "features": {
                "keywords": [
                    "Wind医药",
                    "行业动态"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Wind医药：每日行业动态（2021-10-26）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-10-26",
            "original_text": "凯莱英1.36亿溢价23倍收购医普科诺 三年业绩承诺3600万完善CRO布局",
            "features": {
                "keywords": [
                    "凯莱英",
                    "收购",
                    "医普科诺",
                    "1.36亿",
                    "CRO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "凯莱英1.36亿溢价23倍收购医普科诺 三年业绩承诺3600万完善CRO布局",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]